Genome-Wide Assessment of the Association of Rare and Common Copy Number Variations to Testicular Germ Cell Cancer by Daniel Edsgärd et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 29 January 2013
doi: 10.3389/fendo.2013.00002
Genome-wide assessment of the association of rare
and common copy number variations to testicular germ
cell cancer
Daniel Edsgärd 1, Marlene D. Dalgaard 2, NilsWeinhold 1, AgataWesolowska-Andersen1,
Ewa Rajpert-De Meyts2 *, Anne Marie Ottesen2, Anders Juul 2, Niels E. Skakkebæk 2,Thomas Skøt Jensen1,
Ramneek Gupta1, Henrik Leffers2 and Søren Brunak 1 *
1 Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark
2 Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark
Edited by:
Alberto Ferlin, University of Padova,
Italy
Reviewed by:
Alessandra Mosca, University
Hospital “Maggiore della Carità,” Italy
Frank Weber, University Hospital
Essen, Germany
*Correspondence:
Testis cancer related aspects: Ewa
Rajpert-De Meyts, Department
of Growth and Reproduction,
Rigshospitalet, Blegdams vej 9, 2100
Copenhagen, Denmark.
e-mail: erm@rh.dk;
Bioinformatic aspects: Søren Brunak,
Department of Systems Biology,
Technical University of Denmark,
Kemitorvet 208, 2800 Lyngby,
Denmark.
e-mail: brunak@cbs.dtu.dk
Testicular germ cell cancer (TGCC) is one of the most heritable forms of cancer. Previ-
ous genome-wide association studies have focused on single nucleotide polymorphisms,
largely ignoring the influence of copy number variants (CNVs). Here we present a genome-
wide study of CNV on a cohort of 212 cases and 437 controls from Denmark, which was
genotyped at ∼1.8 million markers, half of which were non-polymorphic copy number
markers. No association of common variants were found, whereas analysis of rare variants
(present in less than 1% of the samples) initially indicated a single gene with significantly
higher accumulation of rare CNVs in cases as compared to controls, at the gene PTPN1
(P =3.8×10−2, 0.9% of cases and 0% of controls). However, the CNV could not be verified
by qPCR in the affected samples. Further, the CNV calling of the array-data was validated by
sequencing of the GSTM1 gene, which showed that the CNV frequency was in complete
agreement between the two platforms. This study therefore disconfirms the hypothesis
that there exists a single CNV locus with a major effect size that predisposes to TGCC.
Genome-wide pathway association analysis indicated a weak association of rare CNVs
related to cell migration (false-discovery rate=0.021, 1.8% of cases and 1.1% of controls).
Dysregulation during migration of primordial germ cells has previously been suspected to
be a part of TGCC development and this set of multiple rare variants may thereby have a
minor contribution to an increased susceptibility of TGCCs.
Keywords: copy number variation, rare variants, testicular germ cell cancers
INTRODUCTION
Testicular germ cell cancer (TGCC) is the most common malig-
nancy in young men aged 15−45 years. The incidence has
increased over the last decades and is highest in the Nordic coun-
tries with 8–9 cases per 100,000, whereas the incidence in men of
African and Asian ancestry is five-fold lower (Chia et al., 2010).
Environmental exposure partly explains the increasing incidence
and ancestral disparity (Skakkebaek et al., 2001), but there is also
evidence of a substantial genetic contribution to TGCC suscep-
tibility. The familial aggregation of TGCC is one of the highest
among cancers. Brothers and sons of TGCC patients have an 8–
10 times and 4–6 times higher risk to develop the disease, while
the risk increases 75- and 35-fold for monozygotic and dizygotic
twins, respectively (Swerdlow et al., 1997; Hemminki and Li, 2004).
Despite the relatively high degree of heritability, genome-wide
familial linkage analyses have not identified any loci predispos-
ing for TGCC, and candidate studies have only found one rare
deletion (2–3%) at the Y chromosome that confers a modest 2–3
fold increased risk (Nathanson et al., 2005). Recently, genome-
wide association studies that search for common single nucleotide
variants associated to TGCC have identified susceptibility loci
at the genes KITLG, SPRY4, BAK1, DMRT1, TERT, and ATF7IP
(Kanetsky et al., 2009; Rapley et al., 2009; Turnbull et al., 2010; Dal-
gaard et al., 2012). The strongest association was found at KITLG
with a greater than 2.5-fold increased risk of disease. Consistent
with the relatively high familial relative risk, this is the largest
effect size found for any single loci among cancers. However, a
considerable portion of the heritability remains to be explained.
Here we investigate constitutional DNA copy number varia-
tions (CNVs) as another source of genetic variability that may
contribute to the development of TGCC. Recent studies have
described associations of common CNVs with neuroblastomas
(Diskin et al., 2009), systemic autoimmunity (Fanciulli et al.,
2007), psoriasis (Hollox et al., 2007), and osteoporosis (Yang et al.,
2008). Rare variants, typically originating from recent and de novo
events, constitute a significant portion of genomic variation. The
thousand genomes project indicates that there are about 20,000
CNVs with allele frequencies down to 1% (1000 Genomes Project
Consortium, 2010; Mills et al., 2011). The contribution of such
rare, or even rarer, variants, to complex disease susceptibility is to
a large extent unknown, but they seem to play an important role
in psychiatric disorders (International Schizophrenia Consortium,
2008; Pinto et al., 2010) and they have been indicated to influence
childhood obesity (Glessner et al., 2010). Further, identification of
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de novo mutations is possible in studies of family-trios and recently
three de novo CNVs were found in 3 out of 43 TGCC trios, a fre-
quency higher than found in two other cancer types (Stadler et al.,
2012), highlighting the paradigm of rare genetic events influencing
susceptibility to TGCC. To date, case-control association studies of
individual rare CNVs have insufficient power to identify disease-
causing variants. To evaluate the impact of rare CNVs with respect
to risk for TGCC, we therefore compared the genome-wide bur-
den of rare CNVs and investigated whether any genes or pathways
were targeted by multiple rare CNVs such that their aggregated
frequency was higher in cases than in controls.
In summary, to assess the effect of CNVs on TGCC we geno-
typed a Danish case-control cohort (Dalgaard et al., 2012) and
analyzed the resulting data with respect to the association of both
common and rare germline CNVs to TGCC.
RESULTS
To identify CNVs that confer a risk to TGCC, we analyzed common
and rare variants in a genome-wide dataset of approximately 1.8
million markers in a Danish cohort constituting 212 TGCC cases
and 437 controls. Application of stringent quality control criteria
for reliable CNV identification (Figure 1) resulted in a final dis-
covery set of 189 cases and 380 controls. Common variants were
defined as CNVs present in more than 1% of the study popula-
tion, and rare variants as CNVs present in no more than 1% of
the studied subjects. Common variants were analyzed with respect
to individual locus association, and rare variants with respect to
overall genetic burden, gene association, and pathway association.
LOCUS ASSOCIATION ANALYSIS
In order to identify common CNVs associated with TGCC, binary
copy number state frequencies of the case and control cohorts were
compared at all loci with CNV frequencies above 1%. We observed
one genome-wide significant deletion at 1p13.3 covering the gene
GSTM1 (P = 0.02, 37.2% cases, 19.5% controls), but downstream
quality control by manual inspection of the copy number inten-
sity histogram at this locus, and application of histogram-based
association analysis (Barnes et al., 2008) suggested a false positive
•1 algorithm
•CNV confidence (LOD < 2)
•CNV length (< 5 markers, < 4kb, > 1Mb)
•Sample burden (n CNVs > 110, total length > 7.5Mb)
•Sample quality 
 (LRR SD (PennCNV) > 0.4, CN variance (Birdsuite) > 2)
≤ 1%
•SegDup region
Burden
•CNV count
•Gene count
•CNV size
•Global CNV length
Gene association
•DGV verification
Pathway association
•Non-European
•Consanguinity
•Inbreeding
•Call rate < 96%
•QC contrast < 0.4
Loci association
•CNVtools verification
•DGV verification
•Boundary truncation artifacts
212 TGCT cases, 437 controls
Genotyped on Affymetrix 6.0
189 TGCT cases, 380 controls
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a
CNV calling + QC
b
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Common CNVs
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d
FIGURE 1 | CNV quality control and analysis. Dashed arrows indicate
CNVs and samples that were excluded from the analysis: (a) quality control of
samples based on SNP calls; (b) quality control of CNVs and samples based
on CNV calls; (c) association analysis of common CNVs; (d) association
analysis of rare CNVs with respect to genomic burden, as well as genes and
pathways with an excess of rare CNVs among cases. See “Materials and
Methods” for further details. LOD, log odds; LRR SD, log R ratio standard
deviation; DGV, database of genomic variants.
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finding (nominal P = 0.26, 51.3% cases, 58.2% controls). A his-
togram of the copy number signal showed three distinct clusters
with 51, 40, and 8% of the cases, respectively, and 58, 37, and 5%
of the controls. The three clusters were assumed to correspond to
copy numbers of 1, 2, and 3. Further, the deletion allele frequency
at this locus has been estimated to be ∼40% in the International
HapMap Phase 3 population study (Altshuler et al., 2010).
Given the varying deletion frequencies reported, and to assess
the quality of the array-data CNV calling, we performed targeted
sequencing of the GSTM1 (chr1p13) gene in 62 patients. The
sequencing data showed three clusters with 52, 40, and 8% of
the samples, and 55 out of the 62 patients were present in the same
clusters as in the array-data. The CNV frequencies of the three
clusters were in perfect agreement with those from the histogram
analysis of the array-data, thereby corroborating that deletion of
GSTM1had no association to TGCC. The sequencing also revealed
that the actual copy numbers were 0, 1, and 2 rather than 1, 2, and
3 since the majority of samples had no DNA present (0 sequence
reads). The reason for that mis-assignment is that a copy number
of 2 is generally assumed by CNV calling software to be the normal
copy number state, having the major allele frequency, whereas in
this case only 5–10% of the population carry two copies of the
gene.
CNV BURDEN ASSOCIATION ANALYSIS
Testing whether individuals with TGCC had a greater genomic
burden of rare CNVs than controls, we observed a weak indica-
tion of increased burden with respect to the number of CNVs per
sample, the number of affected genes per sample, and the average
length of CNVs per sample (case/control ratio: 1.08, 1.10, and 1.11
respectively), and a significant difference with respect to the total
length of all CNVs per sample (case/control ratio: 1.19, P = 0.03;
Table 1).
GENE ASSOCIATION ANALYSIS
Next, we explored if there were any specific genes where rare CNVs
were more common in cases than controls. This analysis did not
require that CNVs found in different samples overlapped each
other, rather, it was sufficient that they were located within the
same genic region. Two genes were found to have genome-wide
significance, PTPN1 (Pemp.= 0.038) and KCNB2 (Pemp.= 0.022),
affecting 0.9 and 1.2% of cases, respectively, whereas no occur-
rence in controls was observed at these loci (Table 2). The CNV at
PTPN1 involved five cases, all found to have a heterozygous dele-
tion at the same intronic region (Figure 2). CNVs at KCNB2 were
found at three different loci: four and one deletions at two differ-
ent introns and one deletion and one duplication at the promoter
(Figure 2). Several CNVs have previously been reported in healthy
individuals at KCNB2, but not at PTPN1 (Database of Genomic
Variants, v. 10), corroborating a true TGCC association at PTPN1,
but weakening the possibility of an actual association to KCNB2.
We attempted to verify the CNV atPTPN1 by performing qPCR
on the affected samples, but all five samples with an indication of a
heterozygous deletion in the array-data were observed to have two
copies in the qPCR. Thus, the CNV calls from the array-data of
PTPN1 are likely to be false positives and no association between
PTPN1 and TGCC can be inferred at this stage.
PATHWAY ASSOCIATION ANALYSIS
Proteins tend to act in concert and perturbations of different com-
ponents in a set of proteins that are interacting in a network
may result in a dysregulation with similar outcome (Lage et al.,
2007; Navlakha and Kingsford, 2010; Pers et al., 2011). We there-
fore conducted association analysis on the level of pathways and
protein–protein interaction networks. Association was assessed in
the same fashion as for genes and loci described above, that is,
by comparing case and control cohorts with respect to the total
frequency of rare CNV events targeting a pathway. We compiled
comprehensive collections of gene sets, where a set of genes either
share function or operate in the same pathway, and performed one
thousand random permutations (shuffling case and control sta-
tus) to estimate a local false-discovery rate (FDR) of each gene set
(Efron and Tibshirani, 2002). We observed a significant differen-
tial proportion of rare CNVs between cases and controls in 14 gene
sets (FDR< 5%, Table 3). However, 11 of these associations were
driven by the gene-specific association to PTPN1 described above.
Table 1 | Global burden of rare CNVs in cases versus controls.
Type Burden P Case:control ratio Baseline (control) Baseline (case)
All Rate 0.09 1.08 4.8 5.17
Gene rate 0.19 1.10 3.3 3.7
Mean length (kb) 0.14 1.11 76.9 85.1
Total length (kb)* 0.03 1.19 372.5 444.3
Duplications only Rate 0.36 1.03 1.9 1.93
Gene rate 0.29 1.09 1.9 2.1
Mean length (kb)* 0.01 1.33 112.3 149.0
Total length (kb) 0.07 1.22 279.4 340.8
Deletions only Rate 0.09 1.12 2.9 3.24
Gene rate 0.23 1.11 1.4 1.6
Mean length (kb) 0.49 1.00 49.9 49.9
Total length (kb) 0.21 1.09 151.6 165.0
*Significant difference (P<0.05). Genome-wide P-values were estimated by 10,000 permutations of case-control status.
www.frontiersin.org January 2013 | Volume 4 | Article 2 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Edsgärd et al. CNV associations to testicular cancer
The three remaining gene sets, which did not include PTPN1,
were: “regulation of cell migration” [go:0030334, 1.8% versus
1.1%, FDR= 0.021, OR= 3.47 (1.12−11.82)],“positive regulation
of catalytic activity” [go:0043085, 1.4% versus 0.5%, FDR= 0.04,
OR= 5.54 (1.31− 32.78)], and “macromolecular complex disas-
sembly” [go:0032984, 2.3% versus 1.9%, FDR= 0.047, OR= 2.47
(1.00−6.23)]. The most significant gene set among all sets tested
was “regulation of cell migration.” A total of 16 individuals har-
bored CNVs that altogether overlapped 14 genes in this pathway,
at 13 unique CNV loci (Table 4). Genes in this gene set that
Table 2 | Genes with an association of rare CNVs.
Gene P1emp. Punadjusted Odds ratio Cases
(%)
Controls
(%)
PTPN1 3.8×10−2 3.9×10−3 12.31 (1.48–568.17) 0.9 0.0
KCNB2 2.2×10−2 4.1×10−4 16.58 (2.19–738.20) 1.2 0.0
1Empirical genome-wide P-values were estimated by 1,000 permutations of
case-control status using Fisher’s test.
were affected in cases but not controls included: BCL2, CDH13,
CORO1A, KDR, MUC2, MUC5AC, ONECUT2, and PTPRK.
DISCUSSION
We assessed the effect of common and rare CNVs in a TGCC
case-control cohort. No single locus was found to be associated to
TGCC, but one potential gene network of interest with a weak sig-
nificant association was identified, having an elevated frequency
of rare CNVs among cases. The absence of any single locus CNV
associated to TGCC is in line with the relatively few findings for
other diseases, including a screening of ∼3,400 common CNVs
in eight common diseases (Craddock et al., 2010). Furthermore,
common CNVs are typically ancient variations, which are tightly
correlated with single nucleotide polymorphisms (SNPs), and can
therefore be detected by genome-wide association studies of com-
mon SNPs (Lander, 2011). However, one should not neglect the
importance of common CNVs in gene-phenotype association
studies, since there exists evidence that disease associated SNPs
have a tendency to tag CNVs more often than random, and that
such CNV-tagging SNPs are enriched for expression quantitative
trait loci (eQTL; Gamazon et al., 2011). Further, rare CNVs are
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FIGURE 2 | Genes with a significant excess of rare CNVs among
cases as inferred from the genome-wide analysis of array-data.
(A) Five cases with deletions and one control with a duplication at an
intron of PTPN1, (B) Six cases with deletions and one case with a
duplication at introns of KCNB2. The bottom track (Database of
Genomic Variants) indicates that many CNVs have previously been
observed at KCNB2 in healthy individuals, whereas none has been
observed at PTPN1.
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Table 3 | Gene sets with an association of rare CNVs.
Gene set type1 Gene set term Posterior2 Local FDR Odds ratio Cases (%) Controls (%)
GO BP Regulation of cell migration 0.98 0.021 3.47 (1.1–11.8) 1.8 1.1
GO BP Macromolecular complex disassembly 0.96 0.040 5.54 (1.3–32.8) 1.4 0.5
GO BP Positive regulation of catalytic activity 0.95 0.047 2.47 (1.0–6.2) 2.3 1.9
1Many sources of gene sets were jointly analyzed but only sets of the type “gene ontology biological process” were significant, apart from gene sets that included
PTPN1, which were excluded from the table.
2The empirical Bayes analysis of microarrays (EBAM) algorithm with 1,000 permutations was used to estimate a posterior and local false discovery rate (FDR) for
every gene set.
Table 4 | CNVs targeting genes that are part of the gene set “Regulation of cell migration.”
CNV Length1 Copy number Sample Class Genes
chr4:55607652. . .55616597 9 1 165855 Case KDR
chr6:128485528. . .128525520 40 1 232996 Case PTPRK
chr6:128864684. . .128871092 6 1 190037 Case PTPRK
chr11:1094626. . .1140711 46 3 210711 Case MUC2, MUC5AC
chr16:29474810. . .30099408 625 1 124873 Case CORO1A
chr16:29488112. . .30085920 598 1 233682 Case CORO1A
chr16:82119367. . .82175095 56 1 224567 Case CDH13
chr16:82408574. . .82502970 94 1 232030 Case CDH13
chr18:52763504. . .53341297 578 3 203688 Case ONECUT2
chr18:59018003. . .59031365 13 1 231734 Case BCL2
chr2:55119289. . .56699138 1580 3 M3088A Control RTN4
chr3:188880305. . .188936673 56 3 M1270A Control SST
chr12:50532205. . .50579767 48 3 M3576A Control ACVRL1
chr15:50811752. . .50882082 70 3 M3047A Control ONECUT1
chr15:97371582. . .97730964 359 3 M053A Control IGF1R
chr19:49893892. . .50298979 405 3 M3381A Control APOE
1Kilobases.
not tagged by common SNPs implicated by GWASs and they have
been found to play a major role in neurodevelopmental disorders
(Merikangas et al., 2009) and rare de novo CNVs were recently
found in 3 out of 43 TGCC family-trios (Stadler et al., 2012). We
have previously searched for CNVs associated to familial TGCTs,
where the inheritance component is much higher than among
sporadic cases, but failed to find a CNV that was significant across
the small set of studied families. We only identified a handful of
CNVs that segregated with TGCT, but these were either family-
specific or relatively common variants, such as RLN1 (Edsgärd
et al., 2011).
The rare association analysis presented in this study initially
indicated two genes to be associated with TGCC, PTPN1, and
KCNB2. KCNB2 was considered a false positive due to the amount
of previously reported CNVs in independent control cohorts at
this locus, being on par with that of the frequency in the case
group of this study. PTPN1 appeared as a good candidate since it
has previously been implicated with the progression of prostate
cancer along with evidence that the androgen receptor is a tran-
scriptional regulator of PTPN1 (Lessard et al., 2010,2012). A loss of
PTPN1 may thereby be associated with impaired responsiveness
to androgens, which would be consistent with the fact that low
androgen status during development is a risk factor for TGCT
(Rajpert-De Meyts and Skakkebaek, 1993; Sonne et al., 2008). Fur-
ther, CNVs at the 20q13 chromosomal region have been observed
in several other cancers (Nishizaki et al., 1998; Schaid, 2004;
Furukawa et al., 2006). Furthermore, all affected probands in this
study presented a deletion, consistent with a tumor suppress-
ing function of oncogenic kinases, and PTPN1 has been shown
to be able to play both a pro- and anti-oncogenic role (Stuible
et al., 2008). A considerable effort was made to ensure high qual-
ity of the CNV calls: by using two complementary CNV calling
methods, by applying several strict QC criteria, and by manual
inspection of the raw probe signals. However, despite the stringent
QC the qPCR did not verify the heterozygous deletion of PTPN1
in any of the samples. This highlights the difficulty of assessing
the reliability of CNV calls from genome-wide short-nucleotide
microarrays.
Our pathway analysis identified the gene set “regulation of cell
migration” as having the highest difference in proportion of rare
CNVs in cases compared to controls. There is a growing body
of information that strongly suggests a crucial role of primordial
www.frontiersin.org January 2013 | Volume 4 | Article 2 | 5
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germ cell (PGC) biology in TGCC oncogenesis. PGCs are embry-
onic cells which during mid-gestation migrate from the base of the
yolk sac, along the hind-gut, to the genital ridge, one of the longest
migrations of all mammalian cells. Four recent SNP GWAS TGCC
studies associated KITLG and a number of other genes related to
the KIT-KITLG pathway (Kanetsky et al., 2009; Rapley et al., 2009;
Turnbull et al., 2010; Dalgaard et al., 2012), a regulatory network
which is believed to be of crucial importance in the determination
of the fate of PGCs (Rapley and Nathanson, 2010). For instance,
mutations of the KIT receptor, or the KIT ligand, in the mouse,
blocks PGC migration, resulting in infertility (Matzuk and Lamb,
2002). In addition, a disturbance of the migration of PGCs during
early fetal development may cause extragonadal germ cell cancers
along the midline of the body (Oosterhuis and Looijenga, 2005).
One of the afflicted genes in the “regulation of cell migration” gene
set was PTPRK, at which two samples had a deletion. Like PTPN1,
PTPRK belongs to the family of protein tyrosine phosphatases, but
it is a membrane-bound receptor. PTRPK has been implicated in
TGFβ-signaling (Xu et al., 2010), and a recent GWAS study indi-
cated the involvement of TGFβ superfamily signaling in testicular
dysgenesis (Dalgaard et al., 2012). In mouse, PGCs divide rapidly
under the influence of TGFβ signaling factors, and defects in PGC
development is observed in knockout models of bone morpho-
genetic proteins (BMPs; Lawson et al., 1999; Ying et al., 2000). In
total there were 14 genes which were part of the “regulation of cell
migration” pathway and that harbored CNVs. It would be of high
interest to further elucidate the role of these genes by studying how
the CNVs affect the expression levels of the corresponding genes.
What may complicate matters is if the critical period of time is
the development of the fetus, which may force one to revert to the
study of animal models.
In the analysis of common CNVs we made a further assess-
ment of the GSTM1 CNV frequency by targeted sequencing. The
main reason for this was to assess the quality of and verify the
array-data CNV calls of a seemingly problematic locus. However,
GSTM1 was also partly chosen due to that the risk of develop-
ing TGCC has been shown to increase by the exposure to certain
environmental factors (Skakkebaek et al., 2001) and GSTM1 is
known to be involved in the detoxification of xenobiotic com-
pounds (Hengstler et al., 1998). Hypothetically, it is not unlikely
that there exists a genetic variation that may affect the ability to
metabolize environmental chemicals, which in turn affects the
risk of TGCC. Apart from such gene-environment interactions
it is probable that part of the unexplained heritability can be
explained by gene–gene interactions, where a combination of sev-
eral genetic variations cause a greater effect on the phenotype than
the sum of their individual effects (epistasis). Further research is
required to assess the effect of rare variants in varying genetic
backgrounds.
In conclusion, this study corroborates the rejection of the
hypothesis that a single CNV locus mediates a major risk for
TGCC. It suggests that several rare CNVs may contribute to the
oncogenesis of a subset of TGCC subjects, but the frequency after
aggregation of CNVs on the implicated gene and pathways is still
low, and these CNVs therefore only provide a minor contribution
to the overall heritability. Larger cohorts are needed to further
explore the impact of rare variants in TGCC.
MATERIALS AND METHODS
SAMPLE COLLECTION
Two hundred and twelve men with TGCCs and 439 healthy
young men with semen concentrations above 60 million sperm/ml
were collected at the Department of Growth and Reproduction,
Rigshospitalet, Denmark. All DNA samples were obtained from
men of Danish ancestry, who provided informed consent for
genetic analysis. The samples were coded during the entire analy-
sis. The project has been approved by the Regional Medical Ethics
Committee (Nr H-KF-265848) and the Danish Personal Data Pro-
tection Agency (Nr 2008-41-2158). This cohort has previously
been analyzed with respect to single nucleotide variation (Dal-
gaard et al., 2012). Sixty-two of the TGCC patients were selected
for sequencing of the GSTM1 gene.
GENOTYPING AND SNP-BASED SAMPLE QUALITY CONTROL
Germline DNA was extracted from peripheral blood using Quick-
Gene DNA whole blood kits from FujiFilm Life Science according
to the manufacturer’s manual. Samples were genotyped using the
Affymetrix Genome-wide Human SNP Array 6.0. Here we present
the analysis of CNVs, SNP association analysis and details of the
cohort are described elsewhere (Dalgaard et al., 2012), but an ini-
tial sample quality control was performed using SNP genotypes
called by the Birdseed algorithm [Affymetrix Power Tools (APT)
v. 1.10.2]. We excluded samples based on a genotyping call rate
below 96%; QC contrast below 0.4 as according to the Affymetrix
GCOS software; non-European ancestry by inspection of a plot of
the first two principal components of the cohort and the HapMap
phase III samples (Altshuler et al., 2010); high degree of related-
ness based on identity-by-descent where one individual was kept
among related samples; and samples with an outlying inbreeding
coefficient.
CNV DETECTION AND QUALITY CONTROL
For samples that passed the SNP quality control described above
we ran two CNV calling algorithms, BirdSuite (v. 1.5.5) and Pen-
nCNV (v. 2010May01). PennCNV requires a signal intensity file
and a SNP genotyping file and these were generated by quan-
tile normalization of PM-only probes with median polish probe
summarization (APT v. 1.12.0) and Birdseed (v. 2 in APT 1.12.0),
respectively. We excluded CNVs which failed any of the four fol-
lowing criteria: (1) A CNV was not called by both algorithms.
A histogram of the percentage of overlap indicates that the vast
majority has >90% overlap, but we set the threshold to at least
10%. (2) A CNV log odds confidence score larger than two, as
recommended by BirdSuite (Korn et al., 2008). (3) CNV size was
less than five markers or four kilobases, in effect excluding the
25% short-length quantile of CNVs. (4) A CNV was longer than
one megabase (three outliers based on histogram). Further, sam-
ples were excluded with respect to the three following criteria: (1)
extreme sample burden in terms of more than 110 CNVs (four
outliers); or (2) a total length of CNVs larger than 7.5 megabases
(two outliers); (3) bad sample quality in terms of high variance
of copy number signal (median copy number variance larger than
two, as recommended by BirdSuite, or a Log R Ratio standard devi-
ation (LRR SD) obtained from PennCNV larger than 0.4). LRR
SD was set according to PennCNV guidelines when CNV calling
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are performed on Affymetrix samples. Finally, rare CNVs that
had more than 50% overlap with segmental duplication regions
(retrieved from UCSC hg18) were removed, since such regions
have been shown to generate more false CNV calls (Pinto et al.,
2010). A total of 189 TGCC cases and 380 controls remained after
the completion of all quality control steps, harboring a total of
1008 and 1872 rare CNVs, respectively.
CNV ASSOCIATION ANALYSIS
Copy number variant association analysis was performed using
plink (v. 1.07) and custom R (v. 2.12) scripts. Common and rare
CNVs were defined as those with an allele frequency above or
below 1%, respectively. The allele frequency of a CNV was deter-
mined using the locus within a CNV region with the maximum
number of overlapping individual CNVs.
LOCUS ASSOCIATION
Common CNVs were evaluated by searching the whole genome
for loci with a significantly higher degree of affected cases as com-
pared to controls. Binary state frequencies were used, and a Fisher
test was performed for deletion, amplification, and any type of
aberration, respectively. Genome-wide significance was estimated
by generating a null distribution based on one thousand case-
control status permutations. For each permutation the minimal
P-value was selected, thereby providing control of the family-
wise error rate (FWER). Loci with significant associations were
further verified by CNVtools (Barnes et al., 2008) which uses a
complementary CNV calling strategy, since it employs a statisti-
cal model based on density-based clustering rather than a hidden
Markov model. Furthermore, loci residing at the edges of a com-
mon CNV and associations from variation of boundary truncation
were excluded.
GLOBAL BURDEN ANALYSIS
The impact of rare CNVs was assessed by three approaches:
genome-burden analysis, gene association, and pathway associ-
ation analysis.
The global burden of rare CNVs in cases compared to controls
were assessed with respect to (i) the number of CNVs per sam-
ple, (ii) the number of affected genes per sample, (iii) the average
length of CNVs per sample, and (iv) the total length of CNVs per
sample.
GENE ASSOCIATION
Gene association analysis was performed using the number of case
and control samples harboring a rare CNV that overlapped the
gene of interest. Genes were retrieved from UCSC (hg18). CNV
frequencies were compared with Fisher’s test and multiple testing
corrected P-values were obtained based on case-control permu-
tation as described above for the locus association of common
CNVs. Significant CNVs which were found to have a lower allele
frequency in our case cohort than in the Database of Genomic
Variants (DGV, v. 10), were considered false positives.
PATHWAY ASSOCIATION
Pathway association analysis was performed based on the number
of case and control samples that had a rare CNV in any of the genes
of a pathway. The R package“siggenes”was used to obtainP-values
corrected for multiple testing across all tested gene sets. The pack-
age provides a FDR, based on randomized case-control sampling,
as well as an adjustment of the variance of an individual pathway
using information from the observed variances of all pathways
(Efron and Tibshirani, 2002). Gene sets were retrieved from KEGG
(Kyoto Encyclopedia of Genes and Genomes; Ogata et al., 1999),
Reactome (D’Eustachio, 2011), BioCarta1, NCI-Nature curated
pathways (Pathway Interaction Database; Schaefer et al., 2009),
GO (Gene Ontology; Ashburner et al., 2000), COSMIC (Catalog of
Somatic Mutations In Cancer; Forbes et al., 2011), Cyclebase (Gau-
thier et al., 2010), protein–protein interaction complexes (Lage
et al., 2007), OMIM (Online Mendelian Inheritance in Man2),
MGI (Mouse Genome Informatics3) and a set of candidate infer-
tility genes from a recent review (Matzuk and Lamb, 2008). Terms
annotating more than 700 or less than 5 genes were discarded,
since they do not produce meaningful statistical results.
VERIFICATION OF PTPN1 COPY NUMBER
Copy number verification of PTPN1 was done using Quantitative
PCR on the Mx3000P platform from Stratagene (Agilent Tech-
nologies, Santa Clara CA, USA). The protocol has been described
previously (Ottesen et al., 2007). Primers for the CNV at PTPN1
were designed using Primer3 (Rozen and Skaletsky, 2000). Primer
sequences for PTPN1 were: forward 5′-TTC AAC CCT AAC TAG
GTA TGC A-3′ and reverse 5′-CTA AAA TGC TGG AGA CTT
AGG T-3′ and primers for GAPDH: forward 5′-CTC CCC ACA
CAC ATG CAC TTA-3′ and reverse 5′-TTG CCA AGT TGC CTG
TCC TT-3′ (DNA Technology A/ S, Aarhus, Denmark). GAPDH
was used as endogenous control gene. Mixtures of forward and
reverse primers were denatured for 3 min at 95˚C and incubated
on ice until use. DNA concentrations were 8–17 ng, 15µL Bril-
liant SYBR Green QPCR Master Mix (Stratagene), 7.0µL primer
mixture of PTPN1 (final conc.: Fw and Rev 100 nm) or GAPDH
(final conc.: Fw and Rev 100 nm), and a total volume of 30µL.
Conditions for amplification were as follows: one cycle at 95˚C for
10 min and 40 cycles at 95˚C for 1 min, 62˚C for 1 min and 72˚C
for 1 min. The PTPN1:GAPDH ratio was calibrated to a normal
male reference control of DNA, as previously described for other
genes (Ottesen et al., 2007; Mau Kai et al., 2008). All specimens
were analyzed in triplicate and the mean-ratio was used to infer
integer copy number.
TARGETED SEQUENCING OF GSTM1
Design of targeted capture baits
Target capture was designed on the Agilent SureSelect capture
system (Santa Clara CA, USA). Baits for capture were designed
by tiling the genomic region harboring GSTM1 with an approxi-
mately 50% overlap between consecutive baits. The bait sequences
were optimized to avoid regions with extreme GC content or
highly variable regions, and to avoid possible cross-hybridization
or self-folding of the baits, which could decrease the hybridization
1http://www.biocarta.com
2http://www.ncbi.nlm.nih.gov/omim
3http://www.informatics.jax.org
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specificity. The principle of this method has been described
previously (Wesolowska et al., 2011).
Library preparation, pooling, target enrichment, and sequencing
DNA shearing, library preparation, and pooling were performed
using a modified protocol of the SureSelect Target Enrichment
System (Agilent Technologies) to allow sample multiplexing as
described elsewhere (Wesolowska et al., 2011). Three micrograms
of genomic DNA was sheared by ultrasound (Covaris; Woburn,
MA, USA) to yield fragments of an average size of ∼200 bp. The
sheared fragments were ligated with custom made adaptors con-
taining a unique four-base barcode, and subsequently purified and
amplified by ligation-mediated PCR (LM-PCR). Amplified DNA
was pooled in groups of 10 with equal amount of each, after which
enrichment was performed by hybridization to custom SureS-
elect target capture baits (Agilent Technologies). The captured
libraries were processed with Illumina Cluster Generation Station
(Illumina, San Diego CA, USA) following the manufactures rec-
ommendations. We performed 100 nt single-end read sequencing
on the Illumina HiSeq 2000 sequencing platform.
Data analysis
Sequence reads were trimmed and high quality reads were
mapped to the human reference genome build 37 (GRCH37)
using Burrow-Wheeler Alignment algorithm (Li and Durbin,
2010). Alignments with mapping score below 30 were discarded
and PCR duplicates were removed with Picard MarkDupli-
cates4. Copy numbers were estimated by calculating a sequence
depth ratio from the number of reads in the targeted genomic
region, normalized by size of the region and total number
of reads for the sample. A histogram of the sequence depth
ratio from all individuals identified three distinct clusters cor-
responding to two copies and heterozygous and homozygous
deletions.
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